{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:57:50Z","timestamp":1779379070644,"version":"3.53.1"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1038\/nrgastro.2013.242","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T13:44:37Z","timestamp":1387287877000},"page":"287-299","source":"Crossref","is-referenced-by-count":55,"title":["Towards personalized care in IBD"],"prefix":"10.1038","volume":"11","author":[{"given":"Mark E.","family":"Gerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot P. B.","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"key":"BFnrgastro2013242_CR1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham, C. & Cho, J. H. Inflammatory bowel disease. N. Engl. J. Med. 361, 2066\u20132078 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013242_CR2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2741\/e473","volume":"4","author":"P Vora","year":"2012","unstructured":"Vora, P., Shih, D. Q., McGovern, D. P. & Targan, S. R. Current concepts on the immunopathogenesis of inflammatory bowel disease. Front. Biosci. (Elite Ed). 4, 1451\u20131477 (2012).","journal-title":"Front. Biosci. (Elite Ed)."},{"key":"BFnrgastro2013242_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","volume":"474","author":"B Khor","year":"2011","unstructured":"Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307\u2013317 (2011).","journal-title":"Nature"},{"key":"BFnrgastro2013242_CR4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng.553","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke, A.  et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat. Genet. 42, 292\u2013294 (2010).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2013242_CR5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","volume":"43","author":"CA Anderson","year":"2011","unstructured":"Anderson, C. A.  et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43, 246\u2013252 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2013242_CR6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","volume":"60","author":"CW Lees","year":"2011","unstructured":"Lees, C. W., Barrett, J. C., Parkes, M. & Satsangi, J. New IBD genetics: common pathways with other diseases. Gut 60, 1739\u20131753 (2011).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L.  et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u2013124 (2012).","journal-title":"Nature"},{"key":"BFnrgastro2013242_CR8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/461724a","volume":"461","author":"PC Ng","year":"2009","unstructured":"Ng, P. C., Murray, S. S., Levy, S. & Venter, J. C. An agenda for personalized medicine. Nature 461, 724\u2013726 (2009).","journal-title":"Nature"},{"key":"BFnrgastro2013242_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky, N. A.  et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142, 46\u201354.e42 (2012).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR10","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2006.08.008","volume":"131","author":"DP McGovern","year":"2006","unstructured":"McGovern, D. P.  et al. TUCAN (CARD8) genetic variants and inflammatory bowel disease. Gastroenterology. 131, 1190\u20131196 (2006).","journal-title":"Gastroenterology."},{"key":"BFnrgastro2013242_CR11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/ibd.21903","volume":"18","author":"L Prideaux","year":"2012","unstructured":"Prideaux, L., De Cruz, P., Ng, S. C. & Kamm, M. A. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm. Bowel Dis. 18, 1340\u20131355 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR12","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1007\/s10620-012-2244-y","volume":"57","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z.  et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig. Dis. Sci. 57, 2944\u20132954 (2012).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrgastro2013242_CR13","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/ibd.22862","volume":"18","author":"A Kaul","year":"2012","unstructured":"Kaul, A.  et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. Inflamm. Bowel Dis. 18, 1872\u20131884 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ajg.2010.505","volume":"106","author":"PL Lakatos","year":"2011","unstructured":"Lakatos, P. L., Papp, M. & Rieder, F. Serologic antiglycan antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 106, 406\u2013412 (2011).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.297.6656.1105","volume":"297","author":"J Main","year":"1988","unstructured":"Main, J.  et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 297, 1105\u20131106 (1988).","journal-title":"BMJ"},{"key":"BFnrgastro2013242_CR16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0171-2985(11)80509-7","volume":"181","author":"JA Rump","year":"1990","unstructured":"Rump, J. A.  et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 181, 406\u2013413 (1990).","journal-title":"Immunobiology."},{"key":"BFnrgastro2013242_CR17","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/0016-5085(91)90657-7","volume":"100","author":"RH Duerr","year":"1991","unstructured":"Duerr, R. H., Targan, S. R., Landers, C. J., Sutherland, L. R. & Shanahan, F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides\/diarrheal illnesses. Gastroenterology 100, 1590\u20131596 (1991).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1053\/gast.1996.v110.pm8964407","volume":"110","author":"EA Vasiliauskas","year":"1996","unstructured":"Vasiliauskas, E. A.  et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 110, 1810\u20131819 (1996).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1128\/IAI.68.3.1542-1548.2000","volume":"68","author":"O Cohavy","year":"2000","unstructured":"Cohavy, O.  et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immun. 68, 1542\u20131548 (2000).","journal-title":"Infect. Immun."},{"key":"BFnrgastro2013242_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/gast.2000.8519","volume":"119","author":"CL Sutton","year":"2000","unstructured":"Sutton, C. L.  et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119, 23\u201331 (2000).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI200420295","volume":"113","author":"MJ Lodes","year":"2004","unstructured":"Lodes, M. J.  et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113, 1296\u20131306 (2004).","journal-title":"J. Clin. Invest."},{"key":"BFnrgastro2013242_CR22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.gastro.2006.04.030","volume":"131","author":"I Dotan","year":"2006","unstructured":"Dotan, I.  et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131, 366\u2013378 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/gut.42.6.788","volume":"42","author":"JF Quinton","year":"1998","unstructured":"Quinton, J. F.  et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42, 788\u2013791 (1998).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0016-5085(99)70087-9","volume":"116","author":"R Panaccione","year":"1999","unstructured":"Panaccione, R. & Sandborn, W. J. Is antibody testing for inflammatory bowel disease clinically useful? Gastroenterology 116, 1001\u20131002 (1999).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR25","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1572-0241.2004.40369.x","volume":"99","author":"A Zholudev","year":"2004","unstructured":"Zholudev, A., Zurakowski, D., Young, W., Leichtner, A. & Bousvaros, A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 99, 2235\u20132241 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR26","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gut.2005.089623","volume":"55","author":"S Joossens","year":"2006","unstructured":"Joossens, S.  et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 55, 1667\u20131669 (2006).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/MIB.0b013e318280b19e","volume":"19","author":"S Plevy","year":"2013","unstructured":"Plevy, S.  et al. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients. Inflamm. Bowel Dis. 19, 1139\u20131148 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0016-5085(03)00385-8","volume":"124","author":"J Halfvarson","year":"2003","unstructured":"Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E. & Jarnerot, G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124, 1767\u20131773 (2003).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1053\/j.gastro.2010.08.049","volume":"139","author":"BP Willing","year":"2010","unstructured":"Willing, B. P.  et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844\u20131854.e1 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR30","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MOG.0b013e32833f1195","volume":"26","author":"J Hansen","year":"2010","unstructured":"Hansen, J., Gulati, A. & Sartor, R. B. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr. Opin. Gastroenterol. 26, 564\u2013571 (2010).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"BFnrgastro2013242_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh, C.  et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205\u2013211 (2006).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR32","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank, D. N.  et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780\u201313785 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2013242_CR33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin, J.  et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59\u201365 (2010).","journal-title":"Nature"},{"key":"BFnrgastro2013242_CR34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/gut.2010.223263","volume":"60","author":"M Joossens","year":"2011","unstructured":"Joossens, M.  et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60, 631\u2013637 (2011).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2011.04.011","volume":"141","author":"P Lepage","year":"2011","unstructured":"Lepage, P.  et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 141, 227\u2013236 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/gut.49.6.777","volume":"49","author":"E Louis","year":"2001","unstructured":"Louis, E.  et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49, 777\u2013782 (2001).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR37","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)90734-5","volume":"347","author":"J Satsangi","year":"1996","unstructured":"Satsangi, J.  et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 347, 1212\u20131217 (1996).","journal-title":"Lancet"},{"key":"BFnrgastro2013242_CR38","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1053\/gast.1997.v112.pm9178675","volume":"112","author":"M Roussomoustakaki","year":"1997","unstructured":"Roussomoustakaki, M.  et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112, 1845\u20131853 (1997).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00054725-200301000-00001","volume":"9","author":"MS Silverberg","year":"2003","unstructured":"Silverberg, M. S.  et al. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm. Bowel Dis. 9, 1\u20139 (2003).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1399-0039.2003.00129.x","volume":"62","author":"T Ahmad","year":"2003","unstructured":"Ahmad, T.  et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 62, 527\u2013535 (2003).","journal-title":"Tissue Antigens"},{"key":"BFnrgastro2013242_CR41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00054725-200411000-00004","volume":"10","author":"L Fernandez","year":"2004","unstructured":"Fernandez, L.  et al. IBD1 and IBD3 determine location of Crohn's disease in the Spanish population. Inflamm. Bowel Dis. 10, 715\u2013722 (2004).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1572-0241.2004.04038.x","volume":"99","author":"B Newman","year":"2004","unstructured":"Newman, B.  et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am. J. Gastroenterol. 99, 306\u2013315 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR43","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/ng.145","volume":"40","author":"SA Fisher","year":"2008","unstructured":"Fisher, S. A.  et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet. 40, 710\u2013712 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2013242_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","volume":"54","author":"EV Loftus Jr","year":"2005","unstructured":"Loftus, E. V. Jr  et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91\u201396 (2005).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR45","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2011.02.046","volume":"140","author":"JH Cho","year":"2011","unstructured":"Cho, J. H. & Brant, S. R. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140, 1704\u20131712 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR46","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/hep.24307","volume":"53","author":"M Janse","year":"2011","unstructured":"Janse, M.  et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 53, 1977\u20131985 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2013242_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","volume":"43","author":"E Melum","year":"2011","unstructured":"Melum, E.  et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat. Genet. 43, 17\u201319 (2011).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2013242_CR48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2307\/585934","volume":"11","author":"C Wells","year":"1952","unstructured":"Wells, C. Ulcerative colitis and Crohn's disease. Ann. R. Coll. Surg. Engl. 11, 105\u2013120 (1952).","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"BFnrgastro2013242_CR49","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.1932.02740680019005","volume":"99","author":"BB Crohn","year":"1932","unstructured":"Crohn, B. B., Ginzburg, L. & Oppenheimer, G. D. Regional ileitis: a pathologic and clinical entity. JAMA 99, 1323\u20131329 (1932).","journal-title":"JAMA"},{"key":"BFnrgastro2013242_CR50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1086\/339432","volume":"70","author":"S Lesage","year":"2002","unstructured":"Lesage, S.  et al. CARD15\/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70, 845\u2013857 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrgastro2013242_CR51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00054725-200309000-00001","volume":"9","author":"SR Brant","year":"2003","unstructured":"Brant, S. R.  et al. Defining complex contributions of NOD2\/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9, 281\u2013289 (2003).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR52","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.3748\/wjg.v12.i44.7097","volume":"12","author":"G Radford-Smith","year":"2006","unstructured":"Radford-Smith, G. & Pandeya, N. Associations between NOD2\/CARD15 genotype and phenotype in Crohn's disease\u2014are we there yet? World J. Gastroenterol. 12, 7097\u20137103 (2006).","journal-title":"World J. Gastroenterol."},{"key":"BFnrgastro2013242_CR53","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/j.1572-0241.2004.40304.x","volume":"99","author":"M Economou","year":"2004","unstructured":"Economou, M., Trikalinos, T. A., Loizou, K. T., Tsianos, E. V. & Ioannidis, J. P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol. 99, 2393\u20132404 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR54","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2007.03.034","volume":"132","author":"NJ Prescott","year":"2007","unstructured":"Prescott, N. J.  et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 132, 1665\u20131671 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR55","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/j.1572-0241.2007.01525.x","volume":"102","author":"RL Roberts","year":"2007","unstructured":"Roberts, R. L.  et al. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am. J. Gastroenterol. 102, 2754\u20132761 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR56","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2008.3","volume":"104","author":"A Latiano","year":"2009","unstructured":"Latiano, A.  et al. Polymorphism of the IRGM gene might predispose to fistulizing behavior in Crohn's disease. Am. J. Gastroenterol. 104, 110\u2013116 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR57","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1572-0241.2007.01660.x","volume":"103","author":"RK Weersma","year":"2008","unstructured":"Weersma, R. K.  et al. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am. J. Gastroenterol. 103, 621\u2013627 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR58","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2007.02.051","volume":"132","author":"M Tremelling","year":"2007","unstructured":"Tremelling, M.  et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 132, 1657\u20131664 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR59","doi-asserted-by":"crossref","first-page":"e52223","DOI":"10.1371\/journal.pone.0052223","volume":"7","author":"C Jung","year":"2012","unstructured":"Jung, C.  et al. Genotype\/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms. PLoS ONE 7, e52223 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2013242_CR60","doi-asserted-by":"crossref","first-page":"e12952","DOI":"10.1371\/journal.pone.0012952","volume":"5","author":"I Cleynen","year":"2010","unstructured":"Cleynen, I.  et al. Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS ONE 5, e12952 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2013242_CR61","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel, J. F.  et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383\u20131395 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013242_CR62","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D'Haens","year":"2008","unstructured":"D'Haens, G.  et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660\u2013667 (2008).","journal-title":"Lancet"},{"key":"BFnrgastro2013242_CR63","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1053\/j.gastro.2008.08.017","volume":"135","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet, L., Bigard, M. A., Malesci, A. & Danese, S. Step-up and top-down approaches to the treatment of Crohn's disease: early may already be too late. Gastroenterology 135, 1420\u20131422 (2008).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/gut.2009.187120","volume":"59","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 59, 141\u2013147 (2010).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR65","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","volume":"17","author":"B Pariente","year":"2011","unstructured":"Pariente, B.  et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm. Bowel Dis. 17, 1415\u20131422 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","volume":"61","author":"L Peyrin-Biroulet","year":"2012","unstructured":"Peyrin-Biroulet, L.  et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 61, 241\u2013247 (2012).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","volume":"130","author":"L Beaugerie","year":"2006","unstructured":"Beaugerie, L., Seksik, P., Nion-Larmurier, I., Gendre, J. P. & Cosnes, J. Predictors of Crohn's disease. Gastroenterology 130, 650\u2013656 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gut.25.6.665","volume":"25","author":"P Rutgeerts","year":"1984","unstructured":"Rutgeerts, P.  et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 25, 665\u2013672 (1984).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR69","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P Rutgeerts","year":"1990","unstructured":"Rutgeerts, P.  et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99, 956\u2013963 (1990).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","volume":"138","author":"F Baert","year":"2010","unstructured":"Baert, F.  et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138, 463\u2013468 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","volume":"133","author":"KF Froslie","year":"2007","unstructured":"Froslie, K. F., Jahnsen, J., Moum, B. A. & Vatn, M. H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133, 412\u2013422 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrgastro.2009.203","volume":"7","author":"G Pineton de Chambrun","year":"2010","unstructured":"Pineton de Chambrun, G., Peyrin-Biroulet, L., Lemann, M. & Colombel, J. F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15\u201329 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR73","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0016-5085(79)90389-5","volume":"77","author":"HS Mekhjian","year":"1979","unstructured":"Mekhjian, H. S., Switz, D. M., Melnyk, C. S., Rankin, G. B. & Brooks, R. K. Clinical features and natural history of Crohn's disease. Gastroenterology 77, 898\u2013906 (1979).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","volume":"231","author":"O Bernell","year":"2000","unstructured":"Bernell, O., Lapidus, A. & Hellers, G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann. Surg. 231, 38\u201345 (2000).","journal-title":"Ann. Surg."},{"key":"BFnrgastro2013242_CR75","first-page":"947","volume":"97","author":"M Allez","year":"2002","unstructured":"Allez, M.  et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol. 97, 947\u2013953 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR76","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/gut.2005.084061","volume":"55","author":"FL Wolters","year":"2006","unstructured":"Wolters, F. L.  et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 55, 1124\u20131130 (2006).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR77","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg, I. C.  et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol. 5, 1430\u20131438 (2007).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR78","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","volume":"43","author":"C Loly","year":"2008","unstructured":"Loly, C., Belaiche, J. & Louis, E. Predictors of severe Crohn's disease. Scand. J. Gastroenterol. 43, 948\u2013954 (2008).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR79","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1111\/j.1572-0241.2008.02212.x","volume":"103","author":"KM Tarrant","year":"2008","unstructured":"Tarrant, K. M., Barclay, M. L., Frampton, C. M. & Gearry, R. B. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am. J. Gastroenterol. 103, 3082\u20133093 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR80","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ajg.2008.38","volume":"104","author":"MJ Romberg-Camps","year":"2009","unstructured":"Romberg-Camps, M. J.  et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am. J. Gastroenterol. 104, 371\u2013383 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR81","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","volume":"139","author":"KT Thia","year":"2010","unstructured":"Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. & Loftus, E. V. Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 139, 1147\u20131155 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR82","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1572-0241.2001.03944.x","volume":"96","author":"L Beaugerie","year":"2001","unstructured":"Beaugerie, L.  et al. Impact of cessation of smoking on the course of ulcerative colitis. Am. J. Gastroenterol. 96, 2113\u20132116 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR83","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/gast.1996.v110.pm8566589","volume":"110","author":"J Cosnes","year":"1996","unstructured":"Cosnes, J., Carbonnel, F., Beaugerie, L., Le Quintrec, Y. & Gendre, J. P. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 110, 424\u2013431 (1996).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.44.1.91","volume":"44","author":"F Carbonnel","year":"1999","unstructured":"Carbonnel, F., Macaigne, G., Beaugerie, L., Gendre, J. P. & Cosnes, J. Crohn's disease severity in familial and sporadic cases. Gut 44, 91\u201395 (1999).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","volume":"87","author":"D Farhi","year":"2008","unstructured":"Farhi, D.  et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore) 87, 281\u2013293 (2008).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrgastro2013242_CR86","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1572-0241.2007.01368.x","volume":"102","author":"M Henriksen","year":"2007","unstructured":"Henriksen, M., Jahnsen, J., Lygren, I., Vatn, M. H. & Moum, B. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am. J. Gastroenterol. 102, 1955\u20131963 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR87","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1111\/j.1572-0241.2007.01265.x","volume":"102","author":"O Hoie","year":"2007","unstructured":"Hoie, O.  et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am. J. Gastroenterol. 102, 1692\u20131701 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR88","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.gastro.2006.11.015","volume":"132","author":"O Hoie","year":"2007","unstructured":"Hoie, O.  et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 132, 507\u2013515 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR89","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/ajg.2009.177","volume":"104","author":"C Gower-Rousseau","year":"2009","unstructured":"Gower-Rousseau, C.  et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am. J. Gastroenterol. 104, 2080\u20132088 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR90","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365520802600961","volume":"44","author":"IC Solberg","year":"2009","unstructured":"Solberg, I. C.  et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand. J. Gastroenterol. 44, 431\u2013440 (2009).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR91","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ibd.20920","volume":"15","author":"JP Gisbert","year":"2009","unstructured":"Gisbert, J. P., McNicholl, A. G. & Gomollon, F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis. 15, 1746\u20131754 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR92","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","volume":"140","author":"JD Lewis","year":"2011","unstructured":"Lewis, J. D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140, 1817\u20131826 e1812 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR93","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.trsl.2012.01.001","volume":"159","author":"HN Iskandar","year":"2012","unstructured":"Iskandar, H. N. & Ciorba, M. A. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl. Res. 159, 313\u2013325 (2012).","journal-title":"Transl. Res."},{"key":"BFnrgastro2013242_CR94","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/gut.2007.146357","volume":"57","author":"M Henriksen","year":"2008","unstructured":"Henriksen, M.  et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 57, 1518\u20131523 (2008).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR95","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2362.1982.tb02244.x","volume":"12","author":"EA Fagan","year":"1982","unstructured":"Fagan, E. A.  et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur. J. Clin. Invest. 12, 351\u2013359 (1982).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrgastro2013242_CR96","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem, C. A.  et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 11, 707\u2013712 (2005).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR97","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","volume":"105","author":"AM Schoepfer","year":"2010","unstructured":"Schoepfer, A. M.  et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am. J. Gastroenterol. 105, 162\u2013169 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR98","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/00365520500419623","volume":"41","author":"KL Kolho","year":"2006","unstructured":"Kolho, K. L., Raivio, T., Lindahl, H. & Savilahti, E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand. J. Gastroenterol. 41, 720\u2013725 (2006).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR99","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ibd.20490","volume":"14","author":"T Sipponen","year":"2008","unstructured":"Sipponen, T.  et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm. Bowel Dis. 14, 1392\u20131398 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365520903483650","volume":"45","author":"T Sipponen","year":"2010","unstructured":"Sipponen, T.  et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand. J. Gastroenterol. 45, 325\u2013331 (2010).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR101","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D'Haens","year":"2012","unstructured":"D'Haens, G.  et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218\u20132224 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/gast.2000.8523","volume":"119","author":"JA Tibble","year":"2000","unstructured":"Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K. & Bjarnason, I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119, 15\u201322 (2000).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR103","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","volume":"54","author":"F Costa","year":"2005","unstructured":"Costa, F.  et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54, 364\u2013368 (2005).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR104","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1572-0241.2008.01870.x","volume":"103","author":"R D'Inca","year":"2008","unstructured":"D'Inca, R.  et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol. 103, 2007\u20132014 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR105","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ibd.20933","volume":"15","author":"JP Gisbert","year":"2009","unstructured":"Gisbert, J. P.  et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis. 15, 1190\u20131198 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR106","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.crohns.2009.09.008","volume":"4","author":"V Garcia-Sanchez","year":"2010","unstructured":"Garcia-Sanchez, V.  et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J. Crohns Colitis 4, 144\u2013152 (2010).","journal-title":"J. Crohns Colitis"},{"key":"BFnrgastro2013242_CR107","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MEG.0b013e32832bab49","volume":"22","author":"L Kallel","year":"2010","unstructured":"Kallel, L.  et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur. J. Gastroenterol. Hepatol. 22, 340\u2013345 (2010).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR108","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2036.2011.04743.x","volume":"34","author":"D Laharie","year":"2011","unstructured":"Laharie, D.  et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment. Pharmacol. Ther. 34, 462\u2013469 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR109","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/MIB.0b013e318280b1cd","volume":"19","author":"J Dabritz","year":"2013","unstructured":"Dabritz, J.  et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm. Bowel Dis. 19, 1130\u20131138 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR110","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4065\/71.5.431","volume":"71","author":"WJ Sandborn","year":"1996","unstructured":"Sandborn, W. J., Landers, C. J., Tremaine, W. J. & Targan, S. R. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin. Proc. 71, 431\u2013436 (1996).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrgastro2013242_CR111","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.49.5.671","volume":"49","author":"PR Fleshner","year":"2001","unstructured":"Fleshner, P. R.  et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49, 671\u2013677 (2001).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR112","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ibd.20781","volume":"15","author":"IC Solberg","year":"2009","unstructured":"Solberg, I. C. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 406\u2013414 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR113","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gut.47.4.487","volume":"47","author":"EA Vasiliauskas","year":"2000","unstructured":"Vasiliauskas, E. A.  et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47, 487\u2013496 (2000).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR114","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.gastro.2003.11.015","volume":"126","author":"WS Mow","year":"2004","unstructured":"Mow, W. S.  et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126, 414\u2013424 (2004).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR115","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1053\/j.gastro.2005.03.046","volume":"128","author":"SR Targan","year":"2005","unstructured":"Targan, S. R.  et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128, 2020\u20132028 (2005).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR116","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1572-0241.2006.00456.x","volume":"101","author":"MC Dubinsky","year":"2006","unstructured":"Dubinsky, M. C.  et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterology. 101, 360\u2013367 (2006).","journal-title":"Am. J. Gastroenterology."},{"key":"BFnrgastro2013242_CR117","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1572-0241.2004.40417.x","volume":"99","author":"ID Arnott","year":"2004","unstructured":"Arnott, I. D.  et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2\/CARD15 genotype. Am. J. Gastroenterol. 99, 2376\u20132384 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR118","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1572-0241.2007.01652.x","volume":"103","author":"M Papp","year":"2008","unstructured":"Papp, M.  et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2\/CARD15 genotype in a Hungarian IBD cohort. Am. J. Gastroenterol. 103, 665\u2013681 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR119","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/gut.2003.030734","volume":"53","author":"DG Forcione","year":"2004","unstructured":"Forcione, D. G., Rosen, M. J., Kisiel, J. B. & Sands, B. E. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53, 1117\u20131122 (2004).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR120","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.gassur.2006.02.004","volume":"10","author":"KG Dendrinos","year":"2006","unstructured":"Dendrinos, K. G.  et al. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J. Gastrointest. Surg. 10, 1060\u20131064 (2006).","journal-title":"J. Gastrointest. Surg."},{"key":"BFnrgastro2013242_CR121","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s10350-007-9158-3","volume":"51","author":"GY Melmed","year":"2008","unstructured":"Melmed, G. Y.  et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum 51, 100\u2013108 (2008).","journal-title":"Dis. Colon Rectum"},{"key":"BFnrgastro2013242_CR122","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ibd.20106","volume":"13","author":"KA Papadakis","year":"2007","unstructured":"Papadakis, K. A.  et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm. Bowel Dis. 13, 524\u2013530 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR123","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2006.108043","volume":"56","author":"M Ferrante","year":"2007","unstructured":"Ferrante, M.  et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56, 1394\u20131403 (2007).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR124","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cgh.2008.04.032","volume":"6","author":"MC Dubinsky","year":"2008","unstructured":"Dubinsky, M. C.  et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin. Gastroenterol. Hepatol. 6, 1105\u20131111 (2008).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR125","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2009.79","volume":"104","author":"CH Seow","year":"2009","unstructured":"Seow, C. H.  et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am. J. Gastroenterol. 104, 1426\u20131434 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR126","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/ibd.21179","volume":"16","author":"F Rieder","year":"2010","unstructured":"Rieder, F.  et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm. Bowel Dis. 16, 1367\u20131375 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR127","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00054725-200102000-00002","volume":"7","author":"S Vermeire","year":"2001","unstructured":"Vermeire, S.  et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm. Bowel Dis. 7, 8\u201315 (2001).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR128","first-page":"631","volume":"52","author":"K Malickova","year":"2006","unstructured":"Malickova, K., Lukas, M., Donoval, R., Sandova, P. & Janatkova, I. Novel anti-carbohydrate autoantibodies in patients with inflammatory bowel disease: are they useful for clinical practice? Clin. Lab. 52, 631\u2013638 (2006).","journal-title":"Clin. Lab."},{"key":"BFnrgastro2013242_CR129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1373\/clinchem.2005.058560","volume":"52","author":"X Bossuyt","year":"2006","unstructured":"Bossuyt, X. Serologic markers in inflammatory bowel disease. Clin. Chem. 52, 171\u2013181 (2006).","journal-title":"Clin. Chem."},{"key":"BFnrgastro2013242_CR130","doi-asserted-by":"crossref","first-page":"e18172","DOI":"10.1371\/journal.pone.0018172","volume":"6","author":"F Rieder","year":"2011","unstructured":"Rieder, F.  et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease\u2014a longitudinal analysis. PLoS ONE 6, e18172 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2013242_CR131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/gut.2008.162420","volume":"58","author":"S Vermeire","year":"2009","unstructured":"Vermeire, S., Van Assche, G. & Rutgeerts, P. Genetic analysis to predict prognosis at the onset of Crohn's disease: not yet ready for prime time? Gut 58, 323\u2013324 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR132","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/ibd.20517","volume":"14","author":"L Hancock","year":"2008","unstructured":"Hancock, L.  et al. Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflamm. Bowel Dis. 14, 1667\u20131677 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/hmg\/ddi494","volume":"15","author":"GT Ho","year":"2006","unstructured":"Ho, G. T.  et al. ABCB1\/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum. Mol. Genet. 15, 797\u2013805 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrgastro2013242_CR134","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/ibd.21293","volume":"16","author":"T Haritunians","year":"2010","unstructured":"Haritunians, T.  et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm. Bowel Dis. 16, 1830\u20131840 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/gast.2002.35393","volume":"123","author":"MT Abreu","year":"2002","unstructured":"Abreu, M. T.  et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123, 679\u2013688 (2002).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR136","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1086\/341124","volume":"71","author":"S Vermeire","year":"2002","unstructured":"Vermeire, S.  et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am. J. Hum. Genet. 71, 74\u201383 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrgastro2013242_CR137","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0140-6736(02)08590-2","volume":"359","author":"J Hampe","year":"2002","unstructured":"Hampe, J.  et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359, 1661\u20131665 (2002).","journal-title":"Lancet"},{"key":"BFnrgastro2013242_CR138","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/gast.2002.32415","volume":"122","author":"AP Cuthbert","year":"2002","unstructured":"Cuthbert, A. P.  et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122, 867\u2013874 (2002).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR139","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000186173.14696.ea","volume":"242","author":"M Alvarez-Lobos","year":"2005","unstructured":"Alvarez-Lobos, M.  et al. Crohn's disease patients carrying Nod2\/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242, 693\u2013700 (2005).","journal-title":"Ann. Surg."},{"key":"BFnrgastro2013242_CR140","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/01.mib.0000235836.32176.5e","volume":"12","author":"J Seiderer","year":"2006","unstructured":"Seiderer, J.  et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm. Bowel Dis. 12, 1114\u20131121 (2006).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR141","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MCG.0b013e318258314d","volume":"47","author":"BF Nasir","year":"2013","unstructured":"Nasir, B. F.  et al. Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. J. Clin. Gastroenterol. 47, 242\u2013245 (2013).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFnrgastro2013242_CR142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ajg.2011.19","volume":"106","author":"J Adler","year":"2011","unstructured":"Adler, J., Rangwalla, S. C., Dwamena, B. A. & Higgins, P. D. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 106, 699\u2013712 (2011).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR143","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2007.144865","volume":"58","author":"RK Weersma","year":"2009","unstructured":"Weersma, R. K.  et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 58, 388\u2013395 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR144","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cgh.2009.05.001","volume":"7","author":"L Henckaerts","year":"2009","unstructured":"Henckaerts, L.  et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin. Gastroenterol. Hepatol. 7, 972\u2013980.e2 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR145","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/gutjnl-2011-300777","volume":"62","author":"I Cleynen","year":"2012","unstructured":"Cleynen, I.  et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 62, 1556\u20131565 (2012).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR146","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOG.0b013e328354be1e","volume":"28","author":"S Vermeire","year":"2012","unstructured":"Vermeire, S., Van Assche, G. & Rutgeerts, P. Classification of inflammatory bowel disease: the old and the new. Curr. Opin. Gastroenterol. 28, 321\u2013326 (2012).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"BFnrgastro2013242_CR147","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","volume":"105","author":"H Sokol","year":"2008","unstructured":"Sokol, H.  et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731\u201316736 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2013242_CR148","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/ibd.22860","volume":"18","author":"S Michail","year":"2012","unstructured":"Michail, S.  et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm. Bowel Dis. 18, 1799\u20131808 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR149","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1221789","volume":"336","author":"ID Iliev","year":"2012","unstructured":"Iliev, I. D.  et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336, 1314\u20131317 (2012).","journal-title":"Science"},{"key":"BFnrgastro2013242_CR150","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1172\/JCI59255","volume":"121","author":"JC Lee","year":"2011","unstructured":"Lee, J. C.  et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170\u20134179 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrgastro2013242_CR151","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ibd.20652","volume":"15","author":"P Alex","year":"2009","unstructured":"Alex, P., Gucek, M. & Li, X. Applications of proteomics in the study of inflammatory bowel diseases: Current status and future directions with available technologies. Inflamm. Bowel Dis. 15, 616\u2013629 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR152","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ibd.21212","volume":"16","author":"G Roda","year":"2010","unstructured":"Roda, G.  et al. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1239\u20131246 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR153","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.clinbiochem.2008.04.021","volume":"41","author":"MA Meuwis","year":"2008","unstructured":"Meuwis, M. A.  et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin. Biochem. 41, 960\u2013967 (2008).","journal-title":"Clin. Biochem."},{"key":"BFnrgastro2013242_CR154","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/ibd.21426","volume":"17","author":"HM Lin","year":"2011","unstructured":"Lin, H. M., Helsby, N. A., Rowan, D. D. & Ferguson, L. R. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm. Bowel Dis. 17, 1021\u20131029 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR155","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.gastro.2006.11.013","volume":"132","author":"SM Devlin","year":"2007","unstructured":"Devlin, S. M.  et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 132, 576\u2013586 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR156","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1136\/gut.2007.125468","volume":"56","author":"L Henckaerts","year":"2007","unstructured":"Henckaerts, L.  et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut 56, 1536\u20131542 (2007).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR157","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1399-0039.2008.01049.x","volume":"71","author":"PL Lakatos","year":"2008","unstructured":"Lakatos, P. L.  et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens 71, 552\u2013559 (2008).","journal-title":"Tissue Antigens"},{"key":"BFnrgastro2013242_CR158","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ibd.20778","volume":"15","author":"PL Lakatos","year":"2009","unstructured":"Lakatos, P. L.  et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2\/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm. Bowel Dis. 15, 365\u2013374 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR159","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/ibd.22884","volume":"18","author":"TB Murdoch","year":"2012","unstructured":"Murdoch, T. B.  et al. Pattern recognition receptor and autophagy gene variants are associated with development of antimicrobial antibodies in Crohn's disease. Inflamm. Bowel Dis. 18, 1743\u20131748 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR160","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ibd.21196","volume":"16","author":"A Ippoliti","year":"2010","unstructured":"Ippoliti, A.  et al. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm. Bowel Dis. 16, 1279\u20131285 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR161","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/ibd.21661","volume":"17","author":"GR Lichtenstein","year":"2011","unstructured":"Lichtenstein, G. R.  et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm. Bowel Dis. 17, 2488\u20132496 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR162","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0b013e318281f275","volume":"19","author":"MC Dubinsky","year":"2013","unstructured":"Dubinsky, M. C.  et al. Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn's Disease. Inflamm. Bowel Dis. 19, 1662\u20131670 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR163","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMe1213371","volume":"367","author":"IS Kohane","year":"2012","unstructured":"Kohane, I. S., Drazen, J. M. & Campion, E. W. A glimpse of the next 100 years in medicine. N. Engl. J. Med. 367, 2538\u20132539 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013242_CR164","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein, G. R., Abreu, M. T., Cohen, R., Tremaine, W. & American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 935\u2013939 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2036.2004.02124.x","volume":"20","author":"J Winter","year":"2004","unstructured":"Winter, J.  et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20, 593\u2013599 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR166","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/j.1572-0241.2005.41900.x","volume":"100","author":"MC Dubinsky","year":"2005","unstructured":"Dubinsky, M. C.  et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100, 2239\u20132247 (2005).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR167","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","volume":"91","author":"I Ordas","year":"2012","unstructured":"Ordas, I., Mould, D. R., Feagan, B. G. & Sandborn, W. J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 91, 635\u2013646 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR168","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2010.236869","volume":"61","author":"N Vande Casteele","year":"2012","unstructured":"Vande Casteele, N.  et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 61, 321 (2012).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR169","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrgastro2013242_CR170","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","volume":"105","author":"W Afif","year":"2010","unstructured":"Afif, W.  et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 1133\u20131139 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR171","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","volume":"11","author":"FS Velayos","year":"2013","unstructured":"Velayos, F. S., Kahn, J. G., Sandborn, W. J. & Feagan, B. G. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin. Gastroenterol. Hepatol. 11, 654\u2013666 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR172","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer, S. B.  et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541\u20131549 (2002).","journal-title":"Lancet"},{"key":"BFnrgastro2013242_CR173","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts, P.  et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462\u20132476 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013242_CR174","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel, J. F.  et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52\u201365 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber, S.  et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239\u2013250 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2013242_CR176","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler, F.  et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58, 492\u2013500 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR177","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","volume":"33","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet, L. & Lemann, M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther. 33, 870\u2013879 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR178","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","volume":"37","author":"E Louis","year":"2002","unstructured":"Louis, E.  et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with \u2212308 TNF gene polymorphism. Scand. J. Gastroenterol. 37, 818\u2013824 (2002).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR179","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/gast.2002.35390","volume":"123","author":"MAS Parsi","year":"2002","unstructured":"Parsi, M. A. S.  et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 123, 707\u2013713 (2002).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR180","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","volume":"97","author":"S Vermeire","year":"2002","unstructured":"Vermeire, S.  et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am. J. Gastroenterol. 97, 2357\u20132363 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR181","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1365-2036.2003.01574.x","volume":"17","author":"ID Arnott","year":"2003","unstructured":"Arnott, I. D., McNeill, G. & Satsangi, J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17, 1451\u20131457 (2003).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR182","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","volume":"9","author":"M Jurgens","year":"2011","unstructured":"Jurgens, M.  et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 9, 421\u2013427.e1 (2011).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2013242_CR183","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1053\/gast.2001.23966","volume":"120","author":"KD Taylor","year":"2001","unstructured":"Taylor, K. D.  et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120, 1347\u20131355 (2001).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR184","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/j.1572-0241.2002.05689.x","volume":"97","author":"N Esters","year":"2002","unstructured":"Esters, N.  et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97, 1458\u20131462 (2002).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ibd.20054","volume":"13","author":"M Ferrante","year":"2007","unstructured":"Ferrante, M.  et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 13, 123\u2013128 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR186","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/ajg.2010.95","volume":"105","author":"M Jurgens","year":"2010","unstructured":"Jurgens, M.  et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. 105, 1811\u20131819 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2013242_CR187","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ibd.21174","volume":"16","author":"MC Dubinsky","year":"2010","unstructured":"Dubinsky, M. C.  et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 16, 1357\u20131366 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR188","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","volume":"2","author":"S Mascheretti","year":"2002","unstructured":"Mascheretti, S.  et al. Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. 2, 127\u2013136 (2002).","journal-title":"Pharmacogenomics J."},{"key":"BFnrgastro2013242_CR189","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2036.2004.01946.x","volume":"20","author":"M Pierik","year":"2004","unstructured":"Pierik, M.  et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment. Pharmacol. Ther. 20, 303\u2013310 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","volume":"123","author":"S Vermeire","year":"2002","unstructured":"Vermeire, S.  et al. NOD2\/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123, 106\u2013111 (2002).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2013242_CR191","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2005.02635.x","volume":"22","author":"T Hlavaty","year":"2005","unstructured":"Hlavaty, T.  et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613\u2013626 (2005).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2013242_CR192","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ibd.20024","volume":"13","author":"T Hlavaty","year":"2007","unstructured":"Hlavaty, T.  et al. Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm. Bowel Dis. 13, 372\u2013379 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR193","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","volume":"58","author":"I Arijs","year":"2009","unstructured":"Arijs, I.  et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612\u20131619 (2009).","journal-title":"Gut"},{"key":"BFnrgastro2013242_CR194","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/ibd.21301","volume":"16","author":"I Arijs","year":"2010","unstructured":"Arijs, I.  et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 16, 2090\u20132098 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000338147","volume":"30","author":"S Vermeire","year":"2012","unstructured":"Vermeire, S. Towards a novel molecular classification of IBD. Dig. Dis. 30, 425\u2013427 (2012).","journal-title":"Dig. Dis."},{"key":"BFnrgastro2013242_CR196","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ibd.21386","volume":"17","author":"CA Siegel","year":"2011","unstructured":"Siegel, C. A.  et al. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm. Bowel Dis. 17, 30\u201338 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrgastro2013242_CR197","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker, E. O.  et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033\u20132045 (2009).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.242","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2013.242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:49:09Z","timestamp":1684468149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2013.242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,17]]},"references-count":197,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["BFnrgastro2013242"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2013.242","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,17]]}}}